+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
MALE
ID07746713

Phase 1 Study of Intravenous JNJ-98768111 in Men With Advanced Prostate Cancer Evaluating Safety and Dosing

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

160

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and appropriate dosing of JNJ-98768111, an antibody drug conjugate targeting Human Kallikrein-2 KLK2, in men with advanced prostate cancer that has spread extensively. The study aims to identify the recommended phase 2 dosing regimen and assess safety at that dose in participants with metastatic prostate cancer who have received prior androgen receptor-targeted therapy. Participants in the first part of the study receive increasing doses of intravenous JNJ-98768111 to determine the best dose regimen. In the second part, participants receive this recommended dose to further evaluate safety. Treatment continues with ongoing androgen deprivation therapy as required. The study is conducted in a sequential design with two parts focusing on dose escalation and safety evaluation. During the trial, participants will have regular assessments to monitor adverse events and dose-limiting toxicities for up to 2 years and 7 months. Researchers will measure drug concentrations, immune responses, tumor response, progression-free survival, prostate-specific antigen PSA changes, and duration of response. Participants are closely monitored for safety and treatment effects throughout the study period.

CONDITIONS

Brief Title

A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here